Figure 10.
The relationship of CD151 expression to clinical outcomes in human cancers. (A-E) Analysis of CD151 expression by RNAseq in TCGA Lung Squamous Cell Carcinoma and Invasive Breast Carcinoma databases. Survival curves are shown for CD151-low cases (Z-score < −1; shown in green) or CD151-high cases (Z-score > 1; shown in red) compared to cases in which CD151 expression was unaltered (shown in black). (A) Reduced CD151 expression was associated with increased overall survival in lung squamous cell carcinomas harboring changes in genes that regulate squamous cell differentiation. (B&C) In less aggressive ESR1+/GATA3+ breast cancers (in which estrogen receptor α (ESR1) or GATA3 were not reduced; see Fig. S8), reduced CD151 expression was associated with reduced survival, while increased CD151 expression was associated with increased survival. (D&E) In the more aggressive ESR1low/GATA3low breast cancer cases, CD151-low cases showed a trend toward increased survival, while CD151-high cases showed reduced overall survival. (F-I) Analysis of CD151 expression in different breast cancer molecular subtypes using KM-plotter to query Affymetrix microarray data. (F) In luminal A breast cancers, CD151-high cases (red) showed increased relapse-free survival compared to CD151-low cases (green). (G) In luminal B breast cancers, no association between CD151 expression and relapse-free survival was observed. (H&I) in Her2+ and basal-like breast cancers, CD151-high cases showed reduced relapse-free survival. In all panels, P values were calculated by the logrank test. More detailed information about the number of cases represented in each panel is found in Table S1.